FDA Accepts Alvotech’s AVT16 – A New Interchangeable Biosimilar to Entyvio
Alvotech’s AVT16 biosimilar to Entyvio is under FDA review, aiming for cheaper, interchangeable treatment for gut diseases.
Alvotech’s AVT16 biosimilar to Entyvio is under FDA review, aiming for cheaper, interchangeable treatment for gut diseases.
The deal brings Firefly’s Firelink platform that precisely targets hard-to-treat KRAS-driven tumors while sparing healthy tissue.
Nurix Therapeutics gets $700M upfront in a potential $2.3B partnership with Roche to co-develop bexobrutideg, a next-gen oral BTK degrader for CLL, MS, and immunology.
Google has placed a major order for over 3 million custom TPUs with Intel in 2028. Nvidia is also testing Intel’s tech as a TSMC backup. Intel shares jumped.
Amazon signed a multibillion deal with Corning for fiber cables to power AI data centers, boosting jobs and stocks.
Oklo bought ARMEC to make nuclear reactor parts faster in-house, boosting control, speed, and clean energy production.